Asset Bee Pollen: Public Notification - Undeclared Drug Ingredient
Audience: Consumer
[Posted 05/12/2014]
ISSUE: The FDA is advising consumers not to purchase or use Asset Bee Pollen, a product promoted and sold for weight loss. FDA laboratory analysis confirmed that Asset Bee Pollen contains sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. These products may also interact, in life-threatening ways, with other medications a consumer may be taking.
BACKGROUND: Asset Bee Pollen is a product promoted and sold for weight loss on various websites. See the Public Notification for a product photo.
RECOMMENDATION: Do not purchase or use Asset Bee Pollen.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
- Complete and submit the report Online: www.accessdata.fda.gov/scripts/medwatch/index.cfm
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[05/12/2014 - Public Notification - FDA]
Related FDA Safety Information:
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.